HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Miranda E Clements Selected Research

OSM-LIF Receptors

12/2021HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer.
1/2021HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Miranda E Clements Research Topics

Disease

2Breast Neoplasms (Breast Cancer)
12/2021 - 01/2021
1Neoplasms (Cancer)
12/2021
1Hypoxia (Hypoxemia)
12/2021
1Neoplasm Metastasis (Metastasis)
01/2021
1Carcinoma (Carcinomatosis)
01/2021

Drug/Important Bio-Agent (IBA)

2Histone Deacetylase InhibitorsIBA
12/2021 - 01/2021
2OSM-LIF ReceptorsIBA
12/2021 - 01/2021
1Histone Deacetylases (Histone Deacetylase)IBA
12/2021
1Histones (Histone)IBA
12/2021
1Oxygen (Dioxygen)IBA
12/2021
1Parathyroid Hormone-Related ProteinIBA
12/2021
1Azacitidine (5 Azacytidine)FDA Link
01/2021
1entinostat (MS 275)IBA
01/2021
1Hypoxia-Inducible Factor 1IBA
01/2021